Ambiq Micro, Inc.
NYSE:AMBQSemiconductors
+$5.10 today
- Market cap
- $1.14B
- Beta
- 5.68
- P/E (TTM)
- -44.8
- EPS (TTM)
- -$1.88
Volume 0.30M
Average 0.58M
AMBQ Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ambiq Micro, Inc.NYSE: AMBQ
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $851K a year earlier. Trailing-twelve-month stock-based compensation was $765K.
Context
- Stock-based compensation amounted to 9.4% of revenue in FY2025, up 2.6 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $191.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.84M USD
- Year-over-year change
- +32.1%
- 5-year CAGR
- +57.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.84M | +32.1% |
| FY2024 | 2024-12-31 | 5.17M | +97.3% |
| FY2023 | 2023-12-31 | 2.62M | — |
| FY2021 | 2021-12-31 | 1.29M | +83.8% |
| FY2020 | 2020-12-31 | 702K | — |
Stock-Based Compensation vs competitors
How AMBQ compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -69.3% is the lowest of 10, against a peer median of -1.9%.
- Stock-based compensation amounts to 0.9% of revenue for AMBQ, versus a peer median of 12.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $42.14M USD | — | — | 13.2% | |
| LTM Mar 2026 | $31.8M USD | -1.9% | +10.9% | 4.5% | |
| LTM Mar 2026 | $30.28M USD | -12.1% | +19.7% | 12.2% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥26.02M CNY | +1.1% | -74.4% | — |
| LTM Mar 2026 | $25.75M USD | +6.2% | -0.9% | 8.5% | |
| LTM Mar 2026 | $19.57M USD | +18.0% | +16.3% | 25.4% | |
| LTM Mar 2026 | $14.21M USD | -53.4% | +15.7% | 9.5% | |
| LTM Mar 2026 | $7.57M USD | -48.0% | +211.3% | 18.7% | |
| LTM Jun 2026 | $3.81M USD | +33.6% | -6.3% | 3.0% | |
| LTM Mar 2026 | $3.4M USD | -36.6% | +11.2% | 240.9% | |
AMBQAmbiq Micro, Inc. | LTM Mar 2026 | $765K USD | -69.3% | — | 0.9% |
| Peer median (excluding AMBQ) | — | -1.9% | +11.2% | 12.2% | |
Competitors are the stored peer set for AMBQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.22M) | (25.34M) | (50.33M) | (39.66M) | (36.46M) |
| Depreciation & Amortization | 1.93M | 2.61M | 7.72M | 6.25M | 7.22M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 702K | 1.29M | 2.62M | 5.17M | 6.84M |
| Change in Working Capital | (16.89M) | (36.58M) | 12.91M | 5.11M | 3.47M |
| Accounts Receivables | (136K) | (10.88M) | (2.98M) | 1.75M | 3.23M |
| Inventory | (3.61M) | (26.46M) | 15.16M | 6.04M | (2.13M) |
| Accounts Payables | (1.55M) | 8.23M | (3.94M) | 821K | 4.2M |
| Other Working Capital | (11.59M) | (7.46M) | 4.67M | (3.51M) | (1.82M) |
| Other Non-Cash Items | 4.84M | 5.14M | 125K | 1.7M | (753K) |
| Operating Cash Flow | (34.64M) | (52.88M) | (26.96M) | (21.43M) | (19.69M) |
| Capital Expenditures | (4.59M) | (4.62M) | (3.02M) | (3.73M) | (1.34M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1.96M) | 0 | (2.56M) | (3.07M) | (6.1M) |
| Investing Cash Flow | (4.59M) | (4.62M) | (3.02M) | (3.73M) | (7.44M) |
| Debt Repayment | 8.77M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 58.84M | 109.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.35M) | 354K | 516K | 0 | (2.83M) |
| Financing Cash Flow | 94.07M | 18.2M | 31.77M | 58.84M | 106.38M |
| Effect of Forex Changes | (53K) | 176K | (254K) | (24K) | 43K |
| Net Change in Cash | 54.78M | (39.13M) | 1.54M | 33.66M | 79.29M |
| Free Cash Flow | (39.23M) | (57.5M) | (29.98M) | (25.16M) | (21.03M) |
Ambiq Micro, Inc.
NYSE:AMBQ
Intrinsic Alpha fair value
Locked
Current Price
$45.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.